HomeCompareBAX vs MET

BAX vs MET: Dividend Comparison 2026

BAX yields 2.28% · MET yields 3.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MET wins by $20.7K in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
MET
MET
● Live price
3.33%
Share price
$68.27
Annual div
$2.27
5Y div CAGR
23%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.3K
Annual income
$4,879.85
Full MET calculator →

Portfolio growth — BAX vs MET

📍 MET pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXMET
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + MET cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
MET pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
MET
Annual income on $10K today (after 15% tax)
$282.63/yr
After 10yr DRIP, annual income (after tax)
$4,147.87/yr
At 15% tax rate, MET beats the other by $4,139.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + MET for your $10,000?

BAX: 50%MET: 50%
100% MET50/50100% BAX
Portfolio after 10yr
$31.0K
Annual income
$2,445.05/yr
Blended yield
7.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MET right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
MET
Analyst Ratings
24
Buy
8
Hold
Consensus: Buy
Price Target
$96.83
+41.8% upside vs current
Range: $90.00 — $101.00
Altman Z
0.1
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
MET buys
8
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MET▲ Buy$1,001 - $15,0002025-09-29
Ro Khanna🏢 House$MET▼ Sell$1,001 - $15,0002025-08-26
Ro Khanna🏢 House$MET▼ Sell$1,000 - $15,0002025-08-26
Gilbert Cisneros🏢 House$MET▼ Sell$1,001 - $15,0002025-08-06
Ritchie Torres🏢 House$MET▼ Sell$1,001 - $15,0002025-07-11
Ro Khanna🏢 House$MET▲ Buy$1,001 - $15,0002025-06-13
Sheldon Whitehouse🏛 Senate$MET▼ Sell$1,001 - $15,0002024-11-19
Thomas R. Carper🏛 Senate$MET▼ Sell$1,001 - $15,0002024-01-17
Ro Khanna🏢 House$MET▲ Buy$1,001 - $15,0002023-10-31
Sheldon Whitehouse🏛 Senate$MET▼ Sell$1,001 - $15,0002023-09-20
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXMET
Forward yield2.28%3.33%
Annual dividend / share$0.36$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%23%
Portfolio after 10y$20.6K$41.3K
Annual income after 10y$10.26$4,879.85
Total dividends collected$602.00$18.1K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusHoldBuy
Analyst price target$19.75$96.83

Year-by-year: BAX vs MET ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrMET PortfolioMET Income/yrGap
1← crossover$10,866$166.33$11,109$408.98$243.00MET
2$11,750$123.31$12,409$522.27$659.00MET
3$12,664$90.97$13,948$670.62$1.3KMET
4$13,617$66.89$15,791$866.52$2.2KMET
5$14,619$49.07$18,024$1,127.71$3.4KMET
6$15,679$35.94$20,765$1,479.66$5.1KMET
7$16,802$26.30$24,179$1,959.61$7.4KMET
8$17,998$19.23$28,494$2,622.90$10.5KMET
9$19,272$14.05$34,042$3,553.25$14.8KMET
10$20,631$10.26$41,305$4,879.85$20.7KMET

BAX vs MET: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

METFinancials

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.

Full MET Calculator →
📬

Get this BAX vs MET comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.